[Edaily Reporter Park Jung-Soo ] Wontech ( WONTECH(336570)), a laser and energy-based medical solutions company, announced on the 22nd that it has signed a trust agreement with SamsungSecurities for the acquisition of 5 billion won worth of its own shares. The planned number of shares to be acquired is 851,788, and the acquisition period is six months, starting today and running through December 22. This share buyback is a measure aimed at enhancing shareholder value and increasing earnings per share. Following its recent decision to cancel treasury shares, WONTECH is expanding its shareholder-friendly policies by proceeding with additional purchases. Previously, on the 18th, WONTECH decided to cancel 300,000 shares of its own stock. The company also canceled 437,749 shares last April, bringing the cumulative total of shares canceled this year to 737,749. The company plans to continue pursuing a capital policy aimed at enhancing shareholder value by simultaneously buying back and canceling its own shares. In particular, the company explained that this latest share repurchase was carried out as an extension of its ongoing shareholder return policy rather than as a means to boost the stock price in the short term. The company plans to strike a balance between growth investments aimed at expanding its global business and shareholder returns. A WONTECH official stated, “The very act of consistently acquiring and canceling treasury shares demonstrates our commitment to shareholder returns through action, not just words,” adding, “We will continue to focus on enhancing long-term shareholder value through a consistent capital policy.”
SamsungElectronics is expected to become the first South Korean company to enter the era of quarterly operating profit exceeding 100 trillion won. Buoyed by a boom in the memory semiconductor market d…
The convenience store industry is expanding its network of specialty stores that focus on specific product categories for each company. With the number of convenience stores in South Korea exceeding 5…
(Graphic: ChatGPT)
Three deals involving Korean companies were included among the top 10 influential transactions in the Asia-Pacific pharmaceutical and biotech market this year. SAMSUNG BIOLOGICS…